Contents lists available at ScienceDirect

Genomics Data



Data in Brief Optimization of gene expression microarray protocol for formalin-fixed paraffin-embedded tissues



Nevin Belder^{a,*}, Öznur Coşkun^b, Beyza Doğanay Erdoğan^c, Berna Savaş^b, Arzu Ensari^b, Hilal Özdağ^a

^a Ankara University, Biotechnology Institute, Ankara, Turkey

^b Ankara University, School of Medicine Department of Pathology, Ankara, Turkey

^c Ankara University, School of Medicine, Department of Biostatistics, Ankara, Turkey

ARTICLE INFO

Article history: Received 2 February 2016 Accepted 5 February 2016 Available online 6 February 2016

Keywords: Microarray Gene expression FFPE Optimization

ABSTRACT

Formalin-fixed paraffin-embedded (FFPE) tissue is a widely available clinical specimen for retrospective studies. The possibility of long-term clinical follow-up of FFPE samples makes them a valuable source to evaluate links between molecular and clinical information. Working with FFPE samples in the molecular research area, especially using high-throughput molecular techniques such as microarray gene expression profiling, has come into prominence. Because of the harmful effects of formalin fixation process such as degradation of nucleic acids, cross-linking with proteins, and chemical modifications on DNA and RNA, there are some limitations in gene expression profiling studies using FFPE samples. To date many studies have been conducted to evaluate gene expression profiling using microarrays (Thomas et al., Thomas et al. (2013) [1]; Scicchitano et al., Scicchitano et al. (2006) [2]; Frank et al., Frank et al. (2007) [3]; Fedorowicz et al., Fedorowicz et al. (2009) [4]). However, there is still no generally accepted, efficient and standardized procedure for microarray analysis of FFPE samples. This paper describes the microarray data presented in our recently accepted to be published article showing a standard protocol from deparaffinization of FFPE tissue sections and RNA extraction to microarray gene expression analysis. Here we represent our data in detail, deposited in the gene expression omnibus (GEO) database with the accession number GSE73883. Four combinations of two different cRNA/cDNA preparation and labeling protocols with two different array platforms (Affymetrix Human Genome U133 Plus 2.0 and U133_X3P) were evaluated to determine which combination gives the best percentage of present call. The study presents a dataset for comparative analysis which has a potential in terms of providing a robust protocol for gene expression profiling with FFPE tissue samples.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND licenses (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Specifications	
Organism/cell line/tissue	Homo sapiens/colon FFPE tissue
Sex	Female
Sequencer or	Affymetrix Human Genome U133 Plus 2.0, Affymetrix
array type	U133_X3P Array
Data format	Raw microarray data (.CEL files) and analyzed data (.CHP files)
Experimental factors	Plus 2.0 + Nugen Ovation FFPE WTA System Kit, X3P Array + Nugen Ovation FFPE WTA System Kit and tumor vs. normal for V2D Array + Nugen Ovation FFPE WTA System Kit and tumor vs. normal for
Experimental features	Four 8-µm-thick colon paraffin-embedded tissue sections were used for RNA extractions. Four different hybridization combinations were performed on four labeled samples using two different kits (Affymetrix 3' IVT kit and the NuGEN Ova- tion FFPE WTA system) and two different arrays (Human

* Corresponding author at: Ankara University, Biotechnology Institute, 06100, Tandogan, Ankara, Turkey.

E-mail addresses: nevinbelder@gmail.com (N. Belder), oznurerd86@gmail.com (Ö. Coşkun), beyzadoganay@gmail.com (B.D. Erdoğan), bsavas@ankara.edu.tr (B. Savaş), ensariarzu@gmail.com (A. Ensari), hilalozdag@gmail.com (H. Özdağ).

Genome U133 Plus 2.0 and U133_X3P arrays). Three of these four samples have matched control samples. Gene expression data analysis was also performed for these three matched samples. Totally, this dataset includes 19 arrays.ConsentInformed consent was obtained from all patients.Sample source locationAnkara University, Faculty of Medicine, Department of Pathology, Ankara, Turkey	Specifications	
	Consent Sample source location	Genome U133 Plus 2.0 and U133_X3P arrays). Three of these four samples have matched control samples. Gene expression data analysis was also performed for these three matched samples. Totally, this dataset includes 19 arrays. Informed consent was obtained from all patients. Ankara University, Faculty of Medicine, Department of Pathology, Ankara, Turkey

1. Direct link to deposited data

http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73883

2. Experimental design, materials and methods

2.1. Experimental design

A comparison study was conducted assessing two different microarray chips and amplification kits for performance comparison. All steps are represented in Fig. 1.

http://dx.doi.org/10.1016/j.gdata.2016.02.006

2213-5960/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).



RNA was extracted from four sporadic colorectal cancer FFPE samples using Qiagen RNeasy extraction kit with modified deparaffinization step. The yield and quality of RNA samples were evaluated using a Nanodrop Spectrophotometer and a Agilent 2100 Bioanalyzer. We assessed microarray performance by comparing four combinations of two different cDNA preparation & labeling protocols and microarray chips. Finally, gene expression data analysis was performed for three matched samples using U133 X3 + NuGEN Ovation FFPE WTA System combination.

2.2. FFPE tissue materials

FFPE tissue samples were obtained from four colon adenocarcinoma patients. Local ethical approval was obtained for using the human material (Research Ethics Committee of Medical Faculty of Ankara University, Ankara Ref: 153-4854). Four different 6–10 year old FFPE blocks were used in this study (08/40 T(TT01), 08/95 T(TT08), 09/137 T(TT24) and 10/12 T(TT31) were collected in 2007, 2005, 2009, and 2006 respectively). Three of these four samples have matched control samples (08/40 T(NT01), 08/95 T(NT08) and 10/12 T(NT31)).

2.3. Characteristics of patients

Four tumor samples and three matched controls of these four samples were used for microarray analysis. All cases were sporadic colorectal cancers from female patients within the age of 27 to 48 years. The histotype of the tumors was conventional adenocarcinoma. The patients had stage III disease and 75% of the patients have left colon sided. All clinico-pathological parameters of the patients are given in Table 1.

2.4. Preparation of FFPE tissue samples and RNA extraction

All steps were performed under RNase-free conditions. Four of 8 µmthick sections were cut from FFPE blocks, on a microtome with a disposable blade. Two of the sections were placed on per microscope slide. The tumor area containing ~90% tumor cells was used for macrodissection.

Four sections were used for RNA extraction. Total RNA was isolated using Qiagen RNeasy FFPE kit (Qiagen, Hilden, Germany) according to the manufacturers' instructions except deparaffinization step. The deparaffinization step was optimized by comparing our laboratory deparaffinization protocol with Qiagen RNeasy FFPE kit's deparaffinization step. These comparisons and their results were given in detail in our manuscript accepted to be published in Pathology Research and Practice [5]. RNA samples extracted from FFPE tissues were analyzed in terms of RNA concentration and purity using NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).

The quality of RNA samples was assessed with RNA 6000 Nano Assay on Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). RNA degradation degree assessment was also checked with PCR which was performed by amplifying seven different amplicon sets that produced fragments ranging from 101 to 246 bp (B2M-101 bp, HPRT-113 bp, VEGFA-168 bp, MAPK14-198 bp, TCF19-201 bp, TGFB1-240 bp, NCAPG-246 bp).

2.5. In vitro transcription, amplification, labeling and hybridization for gene expression analysis

The RNA samples extracted from FFPE samples were amplified and labeled using the 3' IVT kit (Affymetrix, Santa Clara, CA) and the Ovation FFPE WTA System (NuGEN San Carlos, CA, USA). Human Genome U133 Plus 2.0 and U133_X3P arrays were used for hybridization. Four combinations were used to determine which pairwise combination gives the best result in terms of percentage of present call.

Four combinations depicted in Table 2 were applied on the four tumor samples. One of these four combinations was applied on the matched normal samples of three of the four samples. In the combinations where 3' IVT kit (Affymetrix, USA) is used manufacturer's protocol



Fig. 1. A schematic representation of entire experimental workflow.

Table 1				
Clinicopathological	features of fou	r colorectal	cancer j	patients.

Sample name	Tissue	Age	Gender	Histology	Tumor location	Grade	Stage
TT01 tumor_08/40	Colorectal FFPE	26	Female	Adenocarcinoma	Right sided colon	Grade III	Stage IIIB
TT08 tumor_08/95	Colorectal FFPE	46	Female	Adenocarcinoma	Left sided colon	Grade II	Stage IIIB
TT24 tumor_09/137	Colorectal FFPE	32	Female	Adenocarcinoma	Left sided colon	Grade I	Stage IIIB
TT31 tumor_10/12	Colorectal FFPE	48	Female	Adenocarcinoma	Left sided colon	Grade II	Stage IIIB

was followed for all steps. Secondly we assessed NugenRibo-SPIA method for amplification process. In the combinations where Ovation FFPE WTA System (NuGEN San Carlos, CA, USA) is used manufacturer's protocol was followed for the amplification and labeling steps except for the fragmentation performed from 3.5 µg of input cDNA instead of 4– 5 µg recommended in Nugen Ovation FFPE WTA System user guide. The starting RNA amount for cDNA synthesis, the hybridized cRNA (Affymetrix) and cDNA (Nugen) amount and hybridization conditions are given in Table 2. For all four combinations the arrays were washed and stained using user-prepared wash and stain reagents as specified in the Affymetrix GeneChip® Expression Wash, Stain and Scan User Guide (P/N 702731 Rev. 4, pp. 14–20). Gene Chips Fluidics Station 450 is used for the wash and stain step. The hybridized arrays were scanned by a GeneChip Scanner 3000 7G and images were generated using Affymetrix GeneChip Command Console (AGCC) program.

2.6. Statistical data analysis

Two different amplification kits and two different Affymetrix microarray platforms were combined separately for four samples and performance comparison was performed for each pairwise comparison. In addition, we had three samples that were the matched controls of four samples. These three matched normal controls were independently isolated with Qiagen RNeasy FFPE kit, amplified, fragmented and labeled using Nugen Ovation FFPE WTA System for another larger microarray gene expression study. These samples were also hybridized to U133_X3P Array. Gene expression microarray analysis was carried out for three matched tumor and control samples. Totally, our GEO entry has raw data for 19 arrays and 11 of them are for U133_X3P Array and 8 of them are for U133 Plus 2.0. The entire microarray data set has been deposited at the Gene Expression Omnibus (GEO) database with Accession Number GSE73883.

All of the raw data (CEL files) were preprocessed using AffymetrixGeneChip Command Console software (version 3.0.1). The percentage present calls were generated with Affymetrix MAS 5.0 expression algorithm. Group comparisons were performed using

Table 2

Combinations and their corresponding experiment conditions of four colorectal cancers.

CEL data files	HGU133 plus 2.0	X3P array	Affymetrix 3' IVT kit	Nugen ovation FFPE WTA system kit	RNA input	aRNA/cDNA input	Hybridization time/°C
TT01_Nugen_Plus2 TT08_Nugen_Plus2							
TT24_Nugen_Plus2							
TT31_Nugen_Plus2					100 ng	3.5 µg	19 h/45 °C
TT01_IVT_X3P							
TT08_IVT_X3P							
TT24_IVT_X3P							
TT31_IVT_X3P					500 ng	15 µg	16 h/45 °C
TT01_Nugen_X3P							
TT08_Nugen_X3P							
TT24_Nugen_X3P							
TT31_Nugen_X3P					100 ng	3.5 µg	19 h/45 °C
TT01_IVT_Plus2							
TT08_IVT_Plus2							
TT24_IVT_Plus2							
TT31_IVT_Plus2					500 ng	15 µg	16 h/45 °C
NT01_Nugen_X3P							
NT08_Nugen_X3P							
NT31_Nugen_X3P					100 ng	3.5 µg	19 h/45 °C

Student's t test and one-way ANOVA. All analyses were implemented using IBM SPSS Statistics version 20. A p < 0.005 was considered as statistically significant.

Partek Genomic Suite 6.6 software (Partek Inc., St. Louis, MO, USA) was used for paired three tumor and control sample gene expression data analysis. Array data files with a .CEL extension were preprocessed for background correction and quantile normalization using Robust multiarray averaging (RMA). Paired t test was performed to identify differentially expressed genes. Fold-change values of -2 to 2 at a false discovery rate of $\leq 5\%$ and p-value cutoff of 0.001 were used as a filtering criteria to find statistically significantly expressed genes. We then performed unsupervised hierarchical cluster analysis for significant 504 differentially expressed genes to visualize patterns of expression in tumor and control samples. Euclidean distance and average linkage algorithm were used for clustering in the Partek Genomic Suite.

3. Discussion

Here, we provide detailed description of methods for our microarray optimization and comparison study to help reusing of microarray data obtained from FFPE extracted RNA. We believe that our conducted workflow is useful and generally applicable to produce reliable gene expression data from FFPE extracted RNA. These results highlight that FFPE samples can be used as an alternative material to FF tissues for microarray gene expression studies. The entire results were also published in our recent accepted manuscript [5].

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgments

This study is supported with grant no. 109S477 from TUBITAK. Nevin Belder is supported by TUBITAK during this study. The authors thank A. Emre Akpınar for his contribution to figures and tables.

References

- [1] M. Thomas, M. Poignée-Heger, M. Weisser, S. Wessner, A. Belousov, An optimized workflow for improved gene expression profiling for formalin-fixed, paraffinembedded tumor samples. J. Clin. Bioinf. 3 (2013) 10.
- [2] M.S. Scicchitano, D.A. Dalmas, M.A. Bertiaux, S.M. Anderson, L.R. Turner, R.A. Thomas, et al., Preliminary comparison of quantity, quality, and microarray performance of RNA extracted from formalin-fixed, paraffin-embedded, and unfixed frozen tissue samples. J. Histochem. Cytochem. 54 (2006) 1229–1237.
 M. Frank, C. Döring, D. Metzler, S. Eckerle, M.L. Hansmann, Global gene expression profiling of formalin-fixed paraffin-embedded tumor samples: a comparison to

snap-frozen material using oligonucleotide microarrays. Virchows Arch. 450 (2007) 699-711.

- [4] G. Fedorowicz, S. Guerrero, T.D. Wu, Z. Modrusan, Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med. Genet. 2 (2009) 23.
- [5] N. Belder, Ö. Coskun, B.D. Erdogan, B. Savas, A. Ensari, H. Özdag, From RNA Isolation to microarray analysis: comparison of methods in FFPE tissues. Pathol. Res. Pract. (2015), http://dx.doi.org/10.1016/j.prp.2015.11.008.